Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Yan Xiong, Yue Zhong, Hyerin Yim, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 49, pp. 22622-22632
Open Access | Times Cited: 69

Showing 26-50 of 69 citing articles:

Targeted degradation of LRG1 to attenuate renal fibrosis
Linyao Fan, Yingqiu Qi, Xi Yang, et al.
Asian Journal of Pharmaceutical Sciences (2024) Vol. 19, Iss. 4, pp. 100941-100941
Open Access | Times Cited: 5
Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design
Yu Chen, Fengyuan Liu, Samira Pal, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 19, pp. 9582-9608
Closed Access | Times Cited: 5
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
James J. Asciolla, Xuewei Wu, Christos Adamopoulos, et al.
Nature Cancer (2025) Vol. 6, Iss. 1, pp. 24-40
Closed Access
Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function
Yuheng Jin, Xuxin Qi, Xiaoli Yu, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Research Progress in DNA Damage Response (DDR)-Targeting Modulators: from Hits to Clinical Candidates
Binbin Cheng, Zongbao Ding, Yun Hong, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117347-117347
Closed Access
Characterization of MEK1/2 Degraders Uncovers a Kinase-Independent Role for MEK1/2 in the Stabilization and Maturation of CRAF
Jason S. Wasserman, Alison Kurimchak, Carlos Herrera-Montávez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell
Zheng Yuan, Meixia Guo, Yue Zhang, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6
Shuai Zhao, Jingwen Luo, Pingping Xu, et al.
International Journal of Biological Macromolecules (2025), pp. 142667-142667
Closed Access
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation
Zhijie Deng, Jerrel L. Catlett, Youngeun Lee, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Chemically induced degradation of epigenetic targets
Md Kabir, Xufen Yu, H. Ümit Kanıskan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 13, pp. 4313-4342
Open Access | Times Cited: 12
Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons
S.M. Ibrahim, Muhammad Umer Khan, Iqra Khurram, et al.
Food Science & Nutrition (2025) Vol. 13, Iss. 2
Open Access
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Shuoyan Tan, Zhuo Chen, Ruiqiang Lu, et al.
Wiley Interdisciplinary Reviews Computational Molecular Science (2025) Vol. 15, Iss. 2
Closed Access
Strategies for Precise Modulation of Protein Degradation
Shipeng He, Guoqiang Dong, Chunquan Sheng
Accounts of Chemical Research (2025)
Closed Access
The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease
Yu Zhang, Jiahui Yang, Jiali Min, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
The Peptide PROTAC Modality: A New Strategy for Drug Discovery
Youmin Zhu, Yu Dai, Yun-Cai Tian
MedComm (2025) Vol. 6, Iss. 4
Open Access
Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
Yang Zhou, Shujing Xu, Nerea López-Carrobles, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 10
Recent Progress in CDK4/6 Inhibitors and PROTACs
Hao Wang, Jianfei Ba, Yue Kang, et al.
Molecules (2023) Vol. 28, Iss. 24, pp. 8060-8060
Open Access | Times Cited: 10
Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
T. N. Rekha, Dongyun Shin
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5190-5190
Open Access | Times Cited: 9
Overview of PRMT1 Modulators: Inhibitors and Degraders
Jun Wu, Deping Li, Li‐Fang Wang
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116887-116887
Closed Access | Times Cited: 3
Non-coding RNA and drug resistance in head and neck cancer
Yulong Zhang, Yingming Peng, Bingqin Lin, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 3
Bifunctional robots inducing targeted protein degradation
M. Elizabeth Sobhia, Harish Kumar, Sonia Kumari
European Journal of Medicinal Chemistry (2023) Vol. 255, pp. 115384-115384
Closed Access | Times Cited: 7
Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy
Mingming Zheng, Xiaoyu Zhang, Weijiao Chen, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 4, pp. 369-388
Closed Access | Times Cited: 2
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Yaxun Guo, Yuzhan Li, Zhongmei Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Small Molecule Inhibitors Targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for Cancer Immunotherapy (2020-2024)
Binbin Cheng, Jiaoli Lv, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117141-117141
Closed Access | Times Cited: 2
Coming of Age: Targeting Cyclin K in Cancers
Yi Xiao, Jixin Dong
Cells (2023) Vol. 12, Iss. 16, pp. 2044-2044
Open Access | Times Cited: 4

Scroll to top